|
|
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.US |
First Approval Date08 Mar 2004 |
|
MechanismEPO receptor agonists |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. |
First Approval Date08 Jun 2001 |
|
|
Active Org.- |
|
Active Indication- |
|
Drug Highest PhaseWithdrawn |
First Approval Ctry. / Loc. |
First Approval Date22 Aug 2002 |
Open randomized study to evaluate the efficacy of i.v. iron support (ferrum gluconate, 125 mg i.v. infusion weekly for 6 weeks) in primary solid tumour patients (breast, lung, colon-rectum and gynecological) treated with darbepoetin alfa (150 mcg once weekly subcutaneous for 12 weeks)for neoplastic chemotherapy related anaemia.
100 Clinical Results associated with Dompe Biotec SpA
0 Patents (Medical) associated with Dompe Biotec SpA
100 Deals associated with Dompe Biotec SpA
100 Translational Medicine associated with Dompe Biotec SpA